ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2025

Jun 2, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2025-05-29

Reporting Person: Gilliland Robertson H. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-29	Stock Option (Right to Buy)	$0.688	A	28000	Acquired	2035-05-28	Common Stock (28000)	Direct

Footnotes

F1: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.